Abstract
On 11 February 2016, the Medicines and Healthcare Products Regulatory Agency announced that nivolumab, a new medicine for advanced renal cell carcinoma, will be available via the Early Access to Medicines Scheme. Kim Edmonds discusses the impact of this for patients with kidney cancer.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
